<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Bevacizumab; Osteonecrosis of the jaw" /><meta name="IX" content="Bevacizumab; Osteonecrosis of the jaw" /><title>Bevacizumab: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5433-bevacizumab.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5433-bevacizumab.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5433-bevacizumab.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5431-arsenic-trioxide.htm" title="Previous: ARSENIC TRIOXIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5436-bevacizumab.htm" title="Next: BEVACIZUMAB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a304008.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/20782-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Bevacizumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: B &gt; Interactions of Bevacizumab</p></div></li></ul><ul><li><h3>British National Formulary (4)</h3></li><li><a href="PHP4653-bisphosphonates.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bisphosphonates</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 6 Endocrine system &gt; 6.6 Drugs affecting bone metabolism &gt; 6.6.2 Bisphosphonates and other drugs affecting bone metabolism</p></div></li><li><a href="PHP5436-bevacizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">BEVACIZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Bevacizumab</p></div></li><li><a href="PHP5437-avastin.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Avastin®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Bevacizumab &gt; BEVACIZUMAB</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22bevacizumab%22%22osteonecrosis+of+the+jaw%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>BNF for Children</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13464-bisphosphonates.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">6.6.2 Bisphosphonates</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 6 Endocrine system &gt; 6.6 Drugs affecting bone metabolism</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20782-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/01191.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; B &gt; BE</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-B35.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; B</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D923.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Bevacizumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; B</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Bevacizumab</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Bevacizumab</strong> is a monoclonal antibody that inhibits vascular endothelial growth factor. It is licensed for the treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy (but see NICE guidance below). It is also licensed for first-line treatment of metastatic breast cancer in combination with paclitaxel, or with capecitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate; patients who have received adjuvant taxane or anthracyline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capecitabine. Bevacizumab is also licensed for advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a (but see <a title="BNF:target-block: Bevacizumab nice guidance" href="PHP5514-protein-kinase-inhibitors.htm#PHP5525">NICE Guidance</a>). Bevacizumab, in combination with platinum-based chemotherapy, is licensed for first-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. It is also licensed, in combination with carboplatin and paclitaxel, for the first-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Bevacizumab is given by intravenous infusion.</p><div id="PHP5434" class="cI"><p class="cAE">MHRA/CHM advice</p><h3 class="cT">Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)</h3><p>Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p><p>Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p><p>Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.</p><p>If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p></div><p>The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (April 2012) that bevacizumab (<em>Avastin</em>®) is <strong>not</strong> recommended for use within NHS Scotland for the the first-line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.</p><div id="PHP5435" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)</h3><p>Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is <strong>not</strong> recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance <a title="Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE guidance" href="PHP5450-cetuximab.htm#PHP18395">Cetuximab, bevacizumab and panitimumab for the treatment of metastatic colorectal cancer after first-line chemotherapy</a>.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</h3><p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <strong>not</strong> recommended for the treatment of metastatic colorectal cancer.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011)</h3><p>Bevacizumab in combination with a taxane is <strong>not</strong> recommended for the first-line treatment of metastatic breast cancer.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5436-bevacizumab"><a href="PHP5436-bevacizumab.htm" title="BEVACIZUMAB">BEVACIZUMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5431-arsenic-trioxide.htm">Previous: ARSENIC TRIOXIDE</a> | <a class="top" href="PHP5433-bevacizumab.htm#">Top</a> | <a accesskey="]" href="PHP5436-bevacizumab.htm">Next: BEVACIZUMAB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>